Qiagen NV - Company Profile
Powered by
All the data and insights you need on Qiagen NV in one report.
- Save hours of research time and resources with
our up-to-date Qiagen NV Strategy Report
- Understand Qiagen NV position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company’s sample technologies help isolate and process DNA, RNA, and proteins from samples such as blood, tissue and other materials; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers products directly and through a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.
Qiagen NV premium industry data and analytics
Products and Services
Products | Services |
---|---|
- | - |
Sample Technologies: | Laboratory and Genomic Services |
Primary Sample Technology Consumables | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | New Products/Services | In April, the company introduced the QIAseq xHYB Mycobacterium tuberculosis Panel. |
2024 | Plans/Strategy | In April, the company announced its plans to introduce QIAcuity dPCR PanCancer Kits, QIAseq Targeted RNA-seq Panel for T-cell receptors, and PAXgene Urine Liquid Biopsy Set. |
2024 | Contracts/Agreements | In March, the company entered into a partnership with International Panel Physicians Association to train panel physicians about the latest tuberculosis screening requirements. |
Competitor Comparison
Key Parameters | Qiagen NV | Thermo Fisher Scientific Inc | Roche Diagnostics International Ltd | Hologic Inc | 2invest AG |
---|---|---|---|---|---|
Headquarters | Netherlands | United States of America | Switzerland | United States of America | Germany |
City | Venlo | Waltham | Rotkreuz | Marlborough | Heidelberg |
State/Province | - | Massachusetts | Zug | Massachusetts | Baden-Wurttemberg |
No. of Employees | 5,967 | 122,000 | 2,600 | 6,990 | 2 |
Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Thierry Bernard | Chief Executive Officer; Managing Director | Senior Management | 2020 | 58 |
Roland Sackers | Managing Director; Chief Financial Officer | Senior Management | 2006 | 54 |
Lawrence A. Rosen | Chairman | Non Executive Board | 2020 | 65 |
Antonio Santos | Senior Vice President; Head - Global Operations | Senior Management | 2022 | - |
Dr. Jonathan Sheldon | Head - QIAGEN Digital Insights Business Area; Senior Vice President | Senior Management | 2018 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer